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EuPACa: An Opportunity for EuPA to co-ordinate and 
promote Prostate Cancer Proteomics in Europe as 
part of Global Initiatives.
How quickly the months wizz by? Not so long go were in the 
month of November – known by some by its ‘proper’ name 
Movember. Movember marks an important time when many 
men - and a few very brave women – grow moustaches 
(or in the case of women draw them on their upper lip) to 
raise awareness and money for men’s healthcare research. 
The Movember Foundation (www.movember.com), which 
initiated this successful campaign, focused its initial efforts 
on distributing the funds raised to prostate cancer research. 
In its early stages the funding was delivered through national 
cancer research agencies. Subsequently, in an effort to pro-
mote international collaboration the Movember organization 
introduced an on-going series of Global Action Plans (GAPs) to 
complement national funding efforts (Fig. 1). There are currently 
5 GAPs and a number of European proteomics scientists play 
a part in these collaborative projects to identify and evaluate 
protein biomarkers in tissue, blood, urine, exosomes and cir-
culating tumor cells. The proteomics part of these programs is 
undertaken in an interdisciplinary approach alongside genomic, 
epigenetic and other strategies. 
Figure 1. GLOBAL ACTION PLAN (GAP): taken from the Movember  website 
(www.movember.com). The GAPs consist out of 350 top prostate and 
 testicular cancer researchers from 90 institutions all over the world. The 
Global Action Plan (GAP) facilitates a new level or research collaboration 
not previously seen within the cancer community. The engagement of the 
EuPACa proteomics network with this GAP and other initiatives promises 
to be very important.
One of the driving aims of those involved in the Movember 
GAP Prostate Cancer initiatives has been to forward results of 
research into clinical practice – to improve the quality of life 
for men with prostate cancer. 
Since these GAP initiatives have gained momentum it has 
become apparent that proteomics has matured to the point 
where it now plays a critical role in the development of new 
concepts of cancer pathogenesis and that proteomics methods 
are increasingly relevant to and being applied in the ﬁ eld of clini-
cal diagnostics. In this context, it is highly signiﬁ cant that there 
have been some key developments in the diagnosis of bacterial 
 infections. MALDI analysis of proteins has revolutionized microbi-
ology laboratories in recent years including in hospital clinical di-
agnostic labs. It is estimated that as of today the implementation 
of this mass spectrometry based technology is thought to save 
about 19,000 USD per patient hospitalization [see Arch Pathol Lab 
Med, 2013. 137(9): p. 1247-54]. As importantly, this new approach 
and its implementation in clinical labs has provided a clear path-
way for protein based molecular diagnostic tests in cancer to 
reach the required level of analytical and clinical ‘certiﬁ cation’ 
for their use as routine diagnostic tools. So, proteomics research-
ers can now see the opportunity for their lab endeavours to reach 
clinical utility. Methods for multiplexed quantiﬁ cation of candi-
date biomarkers including prostate cancer biomarkers can now 
be achieved either by SRM/MRM based analysis on triple quad-
rupole instruments or PRM type strategies on high-resolution 
instruments. Such methods and their development to clinical 
application are actively being pursued by groups of European 
proteomics researchers who can see a route by which they 
may now contribute to some of the key unmet clinical needs in 
prostate cancer. This includes active engagement with global 
organizations such as Movember.
EuPA is ideally placed to promote, co-ordinate and contribute 
to global prostate cancer research efforts including those of 
the Movember Foundation. The overlap between EuPA’s aims 
and the objectives for the GAP initiatives of Movember (Fig. 2) 
which seek to promote the sharing of knowledge, avoid 
duplication and create collaborations to accelerate translation 
of this knowledge to improve health outcomes, is obvious. 
EuPA could co-ordinate the prostate cancer proteomics efforts 
of European researchers by: 
• creating an active network and database of EU prostate 
cancer proteomics scientists and their on-going 
research projects and interactions between them,
• promoting the dissemination and raising awareness 
of the fundamental knowledge of new proteomic 
strategies for combatting prostate cancer, and
• contributing to the education and training of young 
cancer proteomics researchers.
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Figure 2. The Movember Foundation – Global Collaborators: Taken 
from Movember website (www.movember.com)
The aim of this introductory article is to promote, comment 
and discuss the intention by EuPA members to form an 
active and well connected group of proteomics researchers, 
who, through collaborative efforts, can increase proteomic 
research activity in prostate cancer in Europe and connect 
it with similar efforts worldwide. For such an effort to be 
successful it will need to be inclusive, forward looking 
and develop the credibility and ‘authority’ to make an 
impact. This should include promoting the funding of 
 proteomics activities that have the potential to impact on 
prostate cancer research and prostate cancer patients them-
selves. All those interested in this initiative are therefore 
invited to join the discussion (Linkedin Group: https://www.
linkedin.com/groups/8460418 ) and to meet for a workshop 
session at the Xth EuPA meeting in Istanbul (June, 2016). 
One of the major goals in this initiative –we suggest to call 
it EuPACa (pronounced: ‘upacca’) - is the connection of 
researchers in different proteomic ﬁ elds to gain the most 
beneﬁ cial output from their combined research efforts 
for the development of new proteomic approaches for the 
diagnosis and treatment of prostate cancer (Box 1).
The Linkedin group will facilitate the establishing of a commu-
nity of prostate cancer researchers who will be ready for the 
next Movember grant calls (February 2017) and other European 
initiatives. Additionally, it is hoped that the participation of 
clinicians in the EuPACa group and the ability to link to 
patient sample biobanks coordinated through Movember will be 
invaluable for the proteomics community and accelerate 
research goals and outcomes to improve the lives of the many 
men diagnosed with prostate cancer. 
Thanks for joining these efforts.
Figure 3. A Mo’tley Crew. Growing or drawing a moustache next No-
vember – sorry – that should read ‘Movember’, is not an obligation. 
Who knows maybe one could be sponsored NOT to grow one? The 
evidence presented here suggests that some European Proteomic re-
searchers might possibly have signiﬁ cantly greater success with the 
latter strategy?
BOX 1: Prostate Cancer (adapted from Infographics; see http://
prostatecanceruk.org)
Communicated by:
Corinna Henkel, Leibniz-Institut fuer Analytische 
Wissenschaften - ISAS - e.V. (Germany)
Stephen R Pennington, School of Medicine, UCD Conway 
Institute of Biomolecular and Biomedical Research, 
University College Dublin, Dublin (Ireland)
Andrea Urbani, Proteomics and Metabonomics Laboratory, 
Istituto di Ricovero e Cura a Carattere Scientiﬁ co (IRCCS) 
S. Lucia Foundation, 00179 Rome (Italy)
	(	)"
%$	
$
!"
$
	%
	
 " '%
#   
%&%
	" "
 % 
"%
$	
  
%

What is my risk of prostate cancer?
Prostate cancer mainly affects men over 50
and your risk increases with age. 
The average age for men to be diagnosed with 
prostate cancer is between 70 and 74 years.
In the UK, about one in eight men will get 
prostate cancer at some point in their lives.
1 in 8
Over 50 years old
Family history and genetics
Your risk of prostate 
cancer might be higher 
if your mother or sister 
has had breast cancer, 
particularly if it was 
linked to faults in the 
genes BRCA1 or BRCA2.  
Black men are more likely to get prostate 
cancer than other men. In the UK, about 
1 in 4 Black men will get prostate cancer 
at some point in their lives.
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Prostate cancer is 
the most common 
cancer in men in 
the UK.
Speak to our Specialist Nurses
0800 074 8383
prostatecanceruk.org
You are two and a half 
times more likely to
get prostate cancer 
if your father or brother
has been diagnosed 
with it, compared with 
a man who has no 
affected relatives.
